kabutan

D.Western Therapeutics Institute, Inc.(4576) Summary

4576
TSE Growth
D.Western Therapeutics Institute, Inc.
100
JPY
0
(0.00%)
Jan 29, 3:11 pm JST
0.65
USD
Jan 29, 1:11 am EST
Result
PTS
outside of trading hours
100.5
Jan 29, 3:11 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.71
Yield
ー%
Margin Trading Ratio
899.63
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
100 JPY 0.65 USD
Previous Close Jan 28
100 JPY 0.65 USD
High Jan 29, 11:22 am
101 JPY 0.66 USD
Low Jan 29, 9:01 am
99 JPY 0.64 USD
Volume
470,200
Trading Value
0.05B JPY 0.31M USD
VWAP
99.75 JPY 0.65 USD
Minimum Trading Value
10,000 JPY 65 USD
Market Cap
5.43B JPY 0.04B USD
Number of Trades
86
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
733
1-Year High Sep 26, 2025
25,219
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 7,002,200
Jan 16, 2026 0 7,112,500
Jan 9, 2026 0 7,193,500
Dec 26, 2025 5,000 7,536,000 1507.20
Dec 19, 2025 0 7,445,900
Company Profile
D.Western Therapeutics Institute, Inc. is a drug discovery venture originating from Mie University, focusing on protein kinase inhibitors and developing glaucoma treatments.
Sector
Pharmaceuticals
D.Western Therapeutics Institute, Inc. conducts research and development of pharmaceuticals in the ophthalmology field, primarily centered on protein kinase inhibitors, and operates a drug discovery business that licenses out its developed products to pharmaceutical companies. Their main product, ripasudil hydrochloride hydrate, has been launched in Japan and Asia as a treatment for glaucoma and ocular hypertension, and is also being developed for expanded use in Fuchs' endothelial corneal dystrophy. Additionally, the ophthalmic surgical aid DW-1002 is currently on sale in Europe and the United States, and is under development in Japan. Clinical trials for their in-house developed product H-1337 are also underway. The company has established an efficient research and development system by utilizing their proprietary Drug Western method and actively collaborating with universities and other companies.